Abstract
The effect of piroxicam on rat polymorphonuclear leucocytes (PMN) has been studiedin vitro andin vivo after the induction of two acute, non specific inflammatory reactions (pleurisies induced by calcium pyrophosphate crystals (CaPP) or isologous serum).
An inhibition of chemotaxis by piroxicam has been demonstrated by two techniques, the filter and agarose assaysin vivo andin vitro. An inhibition of random cell migration has been observed only at the higher drug concentration using agarose assay with CaPP-elicited cells.
Piroxicam also inhibited superoxide anion generation and O2 consumption of CaPP- and serum-elicited cells.
These findings suggest that piroxicam may have a direct effect on PMN responses and that this activity could, at least in part, contribute to its anti-inflammatory properties.
Similar content being viewed by others
References
E.H. Wiseman, Y.H. Chang andJ.G. Lombardino, Arzneim. Forsch26, 1300–1303 (1976).
J.G. Lombardino, Eur. J. Rheum. Inflam.6, 24–35 (1983).
R.N. Brogden, R.C. Heel, T.M. Speight andG.S. Avery, Drugs28, 292–323 (1984).
R. Snyderman, T.R. Tempel andS.E. Mergenhagen, J. Dent. Res.,50, 304–311 (1971).
P. Wilkinson in Chemotaxis and Inflammation (sd ed.), Churchill Livingstone, p. 183 (1982).
S. Abramson, H. Edelson, H. Kaplan, R. Ludewig, G. Weissmann, Am. J. Med.77, 3–6 (1984).
H.B. Kaplan, H.S. Edelson, H.M. Korchak, W.P. Given, S. Abramson andG. Weissmann, Biochem. Pharmac.33, 371–378 (1984).
D. Pham Huy, M. Roch-Arveiller, O. Muntaner andJ.P. Giroud, Eur. J. Pharmacol.111, 251–256 (1985).
J.P. Giroud andM. Roch-Arveiller, Trends Pharmacol. Sci.39, 447–449 (1982).
J.P. Giroud, M. Roch-Arveiller andO. Muntaner, Nvle Rev. Fse Hematol.20, 535–543 (1978).
D.A. Willoughby, C.J. Dunn, S. Yamamoto, F. Capasso, D.A. Deporter andJ.P. Giroud, Agents and Actions5, 35–38 (1975).
S. Boyden, J. exp. Med.115, 453–466 (1962).
H.U. Keller, H. Gerber, M.W. Hess andH. Cottier, Agents and Actions6, 326–339 (1976).
R.D. Nelson, R.G. Quie andR.L. Simmons, J. Immunol.115, 1650–1656 (1975).
S.H. Zigmond andJ.G. Hirsch, J. Exp. Med.137, 387–410 (1973).
R.B. Johnston, B.B. Keel andP. Hara, J. Clin. Invest.55, 1357–1372 (1975).
B.F. Van Gelder andE.C. Slater, Biochim. Biophys. Acta58, 593–595 (1962).
B. Kvarstein, Scand. J. clin. lab. invest.25, 337–348 (1970).
J.P. Giroud, M. Roch-Arveiller andD. Pham Huy, Proc. III int. cong. inflam. Paris 1984 (in press).
W.A. Marasco, J.C. Fantone, R.J. Freer andP. Ward, Am. J. Pathol.111, 273–281 (1983).
D.E. Chenoweth, J.G. Rowe andT.E. Hugli, Fed. Proc.38, 1454 (1979).
M. Roch-Arveiller, A. Perianin, D. Pham Huy andJ.P. Giroud, Pathol. Res. and Practice180 130–135 (1985).
K. Tanaka, K. Kanaoka, M. Egawa, N. Abe, I. Watanabe andS. Hirai, Japan J. Pharmacol.35, 181–191 (1984).
H.S. Edelson, H.B. Kaplan, H.M. Korchak, J.E. Smolen andG. Weissmann, Biochem. Biophys. Res. Commun.104, 247–253 (1982).
H.U. Keller, Handbook of Inflammation 5,I.L. Bonta, M.A. Bray andM.J. Parnham eds. p. 137–165.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pham Huy, D., Roch-Arveiller, M., Lenoir, M. et al. In vitro andin vivo effects of piroxicam on rat polymorphonuclear responsiveness after induction of two acute non-specific inflammatory reactions. Agents and Actions 18, 366–371 (1986). https://doi.org/10.1007/BF01964998
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01964998